Leavell Investment Management Inc. Acquires New Shares in Smith & Nephew plc (NYSE:SNN)

Leavell Investment Management Inc. purchased a new stake in shares of Smith & Nephew plc (NYSE:SNN) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 4,765 shares of the medical equipment provider’s stock, valued at approximately $207,000.

A number of other hedge funds also recently made changes to their positions in SNN. Pinnacle Bank acquired a new stake in shares of Smith & Nephew in the fourth quarter worth approximately $31,000. Liberty Wealth Management LLC acquired a new stake in shares of Smith & Nephew in the fourth quarter worth approximately $46,000. Quantamental Technologies LLC acquired a new stake in shares of Smith & Nephew in the first quarter worth approximately $77,000. O Shaughnessy Asset Management LLC boosted its stake in shares of Smith & Nephew by 214.2% in the first quarter. O Shaughnessy Asset Management LLC now owns 3,557 shares of the medical equipment provider’s stock worth $143,000 after acquiring an additional 2,425 shares during the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in shares of Smith & Nephew by 12.3% in the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,789 shares of the medical equipment provider’s stock worth $152,000 after acquiring an additional 416 shares during the last quarter. Institutional investors own 8.82% of the company’s stock.

NYSE:SNN opened at $45.70 on Friday. Smith & Nephew plc has a 52 week low of $32.22 and a 52 week high of $47.05. The company has a quick ratio of 0.96, a current ratio of 2.00 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $20.14 billion, a P/E ratio of 22.62, a P/E/G ratio of 3.22 and a beta of 0.28. The stock’s fifty day moving average is $44.34 and its two-hundred day moving average is $41.37.

A number of analysts have recently issued reports on the company. Canaccord Genuity reaffirmed a “buy” rating and issued a $6.00 price target on shares of Smith & Nephew in a research note on Friday, May 3rd. Berenberg Bank raised Smith & Nephew from a “hold” rating to a “buy” rating in a research note on Tuesday, July 23rd. Finally, Zacks Investment Research raised Smith & Nephew from a “hold” rating to a “buy” rating and set a $49.00 price objective on the stock in a research note on Tuesday, July 2nd. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $27.50.

Smith & Nephew Profile

Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.

See Also: Market Timing

Institutional Ownership by Quarter for Smith & Nephew (NYSE:SNN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.